PG
AMRX icon

Patten Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Patten Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-308
Closed -$7K – 593
2018
Q3 		$7K Hold
308
– – ﹤0.01% 561
2018
Q2 		$5K Buy
+308
New +$5.41K ﹤0.01% 577

Other funds holding AMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Patten Group's AMRX Position: Q4 2018 in Review

Patten Group sold out of Amneal Pharmaceuticals (AMRX) in Q4 2018, closing a stake of 308 shares — an estimated $7K sold.

Patten Group first reported a position in AMRX in Q2 2018 and held it in 2 quarters. The position peaked at $7K in Q3 2018. 168 funds tracked by Wall St. Rank hold AMRX as of Q4 2018.

  • Patten Group reported no remaining Amneal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Patten Group sold 308 Amneal Pharmaceuticals shares in Q4 2018, an estimated $7K.
  • Patten Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Patten Group's Amneal Pharmaceuticals position peaked at $7K in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2018.

Based on Patten Group's 13F filing for Q4 2018, filed 12 Feb 2019.